Cerdelga
AstraZeneca’s Trixeo gets EU approval for asthma maintenance treatment
Trixeo is the first and only triple-combination therapy approved in the EU for patients 12 years and older, independent of exacerbation history
AstraZeneca’s Imfinzi approved in EU for early gastric and gastro-oesophageal cancers
This is the first and only perioperative immunotherapy approved to treat early gastric cancers
Sanofi settles Lemtrada dispute with Genzyme investors for $315m
The MS drug has been in decline amid increased market competition
EMA and FDA calls for innovative approaches for Gaucher disease medicines
The regulatory agencies also urge a similar method for all paediatric diseases
Lucid behavioural change programmes recognised at PMEA
Agency wins awards for initiatives for AbbVieand Genzyme
Shire picks winner for Gaucher film contest
Argentinianfilm My Daughter takes home the competition's top prize
Genzyme opts into gene silencing therapy for haemophilia
Interim results show positive benefits for ALN-AT3
AZ sells rare cancer drug to Sanofi
French firm’s rare disease unit Genzyme will pay $300m for the treatment
Sanofi rare disease drug a breakthrough, says FDA
Regulator awarded the status to olipudase alfa for metabolic disorder
Genzyme and Ablynx collaborate on multiple sclerosis research
Companies will investigate Nanobodies against MS target
Sanofi gains accelerated review for rare disease drug
New pill for Fabry disease could be approved by the FDA before the end of the year